



Lojuxta

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification ¹ issued on	Commission Decision Issued ² / amended on	Product Information affected ³	Summary
PSUSA/10112 /202107	Periodic Safety Update EU Single assessment - lomitapide	10/03/2022	n/a		PRAC Recommendation - maintenance
S/0048	Annual re-assessment.	24/02/2022	n/a		
II/0046	C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing	24/02/2022		Annex II, Labelling and	

¹ Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

² A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

³ SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).



	authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required			PL	
IA/0050	A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)	08/11/2021	n/a		
II/0047	<p>Introduction of an enhanced pharmacovigilance system to evaluate the occurrence and outcomes of pregnancy in females of reproductive potential treated with lomitapide who decide to continue the pregnancy following advice from a teratologist/clinician, replacing the currently agreed Pregnancy Exposure Register (PER), which is listed as part of the specific obligations in the Annex II. The RMP version 6.5 has also been submitted. In addition, the MAH took the opportunity to introduce minor administrative changes.</p> <p>C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required</p>	28/10/2021	03/12/2021	Annex II	Annex II E is being amended to delete the Pregnancy exposure registry, which is being replaced by an updated Pharmacovigilance system, which introduces also congenital anomalies as an outcome of primary interest.
PSUSA/10112 /202007	Periodic Safety Update EU Single assessment - lomitapide	11/03/2021	n/a		PRAC Recommendation - maintenance

S/0043	7th annual re-assessment	28/01/2021	n/a		The CHMP, having reviewed the evidence of compliance with the specific obligations and the impact of the data submitted by the MAH on the benefit/risk profile of the medicinal product, concluded that marketing authorisation of Lojuxta should be maintained.
IAIN/0045	A.1 - Administrative change - Change in the name and/or address of the MAH	07/12/2020	03/12/2021	SmPC, Labelling and PL	
IA/0042	A.7 - Administrative change - Deletion of manufacturing sites	21/08/2020	n/a		
IA/0041/G	This was an application for a group of variations. B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)	04/08/2020	n/a		
S/0036	Annual re-assessment.	26/03/2020	n/a		
PSUSA/10112 /201907	Periodic Safety Update EU Single assessment - lomitapide	13/02/2020	n/a		PRAC Recommendation - maintenance

IA/0040/G	<p>This was an application for a group of variations.</p> <p>A.7 - Administrative change - Deletion of manufacturing sites</p> <p>A.7 - Administrative change - Deletion of manufacturing sites</p> <p>A.7 - Administrative change - Deletion of manufacturing sites</p> <p>A.7 - Administrative change - Deletion of manufacturing sites</p> <p>A.7 - Administrative change - Deletion of manufacturing sites</p> <p>A.7 - Administrative change - Deletion of manufacturing sites</p>	23/01/2020	09/03/2020	Annex II and PL	
IA/0039/G	<p>This was an application for a group of variations.</p> <p>B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place</p> <p>B.III.1.b.2 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - New certificate for a starting material/reagent/intermediate/or excipient from a new or an already approved manufacturer</p> <p>B.III.1.b.2 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - New certificate for a starting material/reagent/intermediate/or excipient from a new or an already approved manufacturer</p>	11/12/2019	n/a		

	<p>B.III.1.b.2 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - New certificate for a starting material/reagent/intermediate/or excipient from a new or an already approved manufacturer</p> <p>B.III.1.b.2 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - New certificate for a starting material/reagent/intermediate/or excipient from a new or an already approved manufacturer</p> <p>B.III.1.b.3 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Updated certificate from an already approved manufacturer</p> <p>B.III.1.b.3 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Updated certificate from an already approved manufacturer</p> <p>B.III.1.b.3 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Updated certificate from an already approved manufacturer</p> <p>B.III.1.b.4 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Deletion of certificates (in case multiple certificates exist per material)</p>				
IA/0038/G	<p>This was an application for a group of variations.</p> <p>B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP -</p>	27/11/2019	n/a		

	<p>Replacement/addition of a site where batch control/testing takes place</p> <p>B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits</p> <p>B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure</p> <p>B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure</p>				
IAIN/0035	<p>B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing</p>	11/04/2019	n/a		
IAIN/0034/G	<p>This was an application for a group of variations.</p> <p>B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site</p> <p>B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing</p>	11/04/2019	09/03/2020	Annex II and PL	
PSUSA/10112/201807	<p>Periodic Safety Update EU Single assessment - lomitapide</p>	14/02/2019	n/a		PRAC Recommendation - maintenance

S/0032	5th annual re-assessment	31/01/2019	n/a		The CHMP, having reviewed the evidence of compliance with the specific obligations and the impact of the data submitted by the MAH on the benefit/risk profile of the medicinal product, concluded that Marketing Authorisation under exceptional circumstances of Lojuxta should be maintained.
T/0031	Transfer of Marketing Authorisation	27/07/2018	27/08/2018	SmPC, Labelling and PL	
IB/0030	B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)	14/06/2018	27/08/2018	SmPC	
R/0029	Renewal of the marketing authorisation.	22/02/2018	23/04/2018	SmPC, Annex II, Labelling and PL	<p>Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Lojuxta in the approved indication remains favourable, but recommended that one additional five-year renewal be required based on the following pharmacovigilance grounds:</p> <ul style="list-style-type: none"> - Lojuxta was granted a Marketing Authorisation under exceptional circumstances and the MAH committed to complete a number of post-approval commitments within agreed timeframes. One specific obligation is still pending, due to the fact that two registries (LOWER and PER) are still ongoing, which will generate further clinical (safety and effectiveness) data. - Further, considering the safety profile of Lojuxta, the MAH was requested to continue to submit yearly PSURs unless otherwise specified.

II/0028	B.I.a.1.g - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Introduction of a new manufacturer of the AS that is not supported by an ASMF and requires significant update to the relevant AS section in the dossier	15/03/2018	n/a		
PSUSA/10112 /201707	Periodic Safety Update EU Single assessment - lomitapide	08/02/2018	n/a		PRAC Recommendation - maintenance
S/0026	4th annual re-assessment	25/01/2018	n/a		The CHMP, having reviewed the evidence of compliance with the specific obligations and the impact of the data submitted by the MAH on the benefit/risk profile of the medicinal product, concluded that marketing authorisation of Lojuxta should be maintained.
S/0023	3th Annual Re-assessment	23/03/2017	n/a		The CHMP, having reviewed the evidence of compliance with the specific obligations and the impact of the data submitted by the MAH on the benefit/risk profile of the medicinal product, concluded that Marketing Authorisation of Lojuxta should be maintained.
N/0025	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	17/03/2017	23/04/2018	PL	
PSUSA/10112 /201607	Periodic Safety Update EU Single assessment - lomitapide	09/02/2017	n/a		PRAC Recommendation - maintenance
PSUSA/10112 /201601	Periodic Safety Update EU Single assessment - lomitapide	15/09/2016	11/11/2016	SmPC and PL	Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s) for PSUSA/10112/201601.
X/0016	Annex I_2.(c) Change or addition of a new strength/potency	17/12/2015	18/02/2016	SmPC, Annex II, Labelling	

				and PL	
PSUSA/10112 /201507	Periodic Safety Update EU Single assessment - lomitapide	11/02/2016	n/a		PRAC Recommendation - maintenance
S/0020	Annual re-assessment.	19/11/2015	n/a		
PSUSA/10112 /201501	Periodic Safety Update EU Single assessment - lomitapide	10/09/2015	n/a		PRAC Recommendation - maintenance
IA/0019	B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place	21/08/2015	n/a		
IB/0018	C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation	22/07/2015	18/02/2016	Annex II	
IA/0017	B.II.e.4.a - Change in shape or dimensions of the container or closure (immediate packaging) - Non-sterile medicinal products	23/06/2015	n/a		
II/0014/G	This was an application for a group of variations. Grouping of three type II variations as follows: Variation 1 Submission of the CSR for study AEGR-733-024 undertaken to investigate the effect of atorvastatin (a weak CYP3A4 inhibitor) on the pharmacokinetics of lomitapide;	26/02/2015	30/03/2015	SmPC and PL	Data from three drug-drug interaction studies and from literature on effect of CYP3A4 inhibitors have been analysed and justify the recommendation for concomitant dosing separation and adjustment of lomitapide when combined with CYP3A4 inhibitors.

	<p>Variation 2 Submission of the CSR for study AEGR-733-029 undertaken to investigate the effect of Ortho Cyclen (ethinyl estradiol/norgestimate; a weak CYP3A4 inhibitor) on the pharmacokinetics of lomitapide;</p> <p>Variation 3 Submission of the final report related to the validation of a mechanistic (PBPK) model to predict lomitapide interactions with CYP3A4 inhibitors. As a consequence sections 4.2, 4.4 and 4.5 of the SmPC have been updated and the Package Leaflet and the RMP have been updated accordingly. A revised RMP version 5.0 was provided as part of the application.</p> <p>C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data</p> <p>C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data</p> <p>C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data</p>				
PSUSA/10112 /201407	Periodic Safety Update EU Single assessment - lomitapide	12/02/2015	n/a		PRAC Recommendation - maintenance
II/0012	C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission	18/12/2014	n/a		

	of studies to the competent authority				
S/0011	First Annual Re-assessment	20/11/2014	n/a		The CHMP, having reviewed the evidence of compliance with the specific obligations and the impact of the data submitted by the MAH on the benefit/risk profile of the medicinal product, concluded that the Marketing Authorisation of Lojuxta should be maintained.
PSUV/0008	Periodic Safety Update	25/09/2014	19/11/2014	SmPC and PL	Please refer to Lojuxta-EMA-H-C-2578-PSUV-0008 EPAR: Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation.
IAIN/0010	C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location	27/06/2014	n/a		
IB/0007	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	06/06/2014	n/a		
N/0009	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	03/06/2014	19/11/2014	Labelling and PL	
IA/0006/G	This was an application for a group of variations. B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor	28/02/2014	19/11/2014	SmPC	

	<p>changes to an approved test procedure</p> <p>B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure</p> <p>B.II.e.1.a.1 - Change in immediate packaging of the finished product - Qualitative and quantitative composition - Solid pharmaceutical forms</p>				
II/0004	C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority	23/01/2014	n/a		
IB/0003	B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation	10/01/2014	n/a		
T/0002	Transfer of Marketing Authorisation	22/11/2013	18/12/2013	SmPC, Labelling and PL	
IB/0001/G	<p>This was an application for a group of variations.</p> <p>B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation</p> <p>B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure</p> <p>B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure</p>	16/09/2013	n/a		